Human tau in an ultradian light-dark cycle.

Human tau in an ultradian light-dark cycle. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Human tau in an ultradian light-dark cycle. Abstract Text:

Human tau in an ultradian light-dark cycle. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Human tau in an ultradian light-dark cycle. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of biological rhythms

VOLUME: 23

Page Numbers: 374-6

Journal Abbreviation: J. Biol. Rhythms

ISSN: 0748-7304

DAY: 29

MONTH: Aug

YEAR: 2008

Human tau in an ultradian light-dark cycle. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8700115

Human tau in an ultradian light-dark cycle. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Human tau in an ultradian light-dark cycle. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Human tau in an ultradian light-dark cycle.

AFFILIATION: Biological Rhythms Research Laboratory, Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Biol Rhythms

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Human tau in an ultradian light-dark cycle Related Publications

• A compromise phase position for permanent night shift workers: circadian phase after two night shifts with scheduled sleep and light/dark exposure.
• A proposal for the mechanism-of-action of diazoparaquinone natural products.
• A three pulse phase response curve to three milligrams of melatonin in humans.
• Can even minimal news coverage influence consumer health-related behaviour? A case study of iodized salt sales, Australia.
• Changing patterns of bacterial infection.
• DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2.
• Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
• Deoxyribonuclease II in apoptosis and the significance of intracellular acidification.
• Dispatch from Landstuhl.
• Fork it over: the cohesion establishment factor Ctf7p and DNA replication.
• Further observations on the suppository as a contraceptive.
• Human tau in an ultradian light-dark cycle.
• Infant Mortality in Relation to Month of Birth.
• Information fluency for undergraduate biology majors: applications of inquiry-based learning in a Developmental Biology course.
• Long-loop reflexes in the tranquilized monkey.
• Lumbar ganglionectomy in peripheral arteriosclerosis.
• Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
• Niche differentiation among sulfur-oxidizing bacterial populations in cave waters.
• Nutrition in Relation to Pregnancy and Lactation.
• Obstruction of the common duct by stone.
• Pelvic mensuration; a study in the perpetuation of error.
• Phylogenetic Footprinting Analysis in the Upstream Regulatory Regions of the Drosophila Enhancer of split Genes.
• Problems in the evolution of obstetrics.
• Prolactin and the return of ovulation in breast-feeding women.
• Role of chromosome segregation genes in BRCA1-dependent lethality.
• Studies on the mechanism of action of prekinamycin, a member of the diazoparaquinone family of natural products: evidence for both sp2 radical and orthoquinonemethide intermediates.
• The Future of Emergency Care in the United States Health System: an Institute of Medicine report.
• The plasma proteins--recent biochemical advances.
• The plasma proteins-clinical applications.
• p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?